NAT10 and urinary bladder carcinoma: Remodelin, by inhibiting NAT10 expression, has been found to increase bladder cancer patients’ sensitivity to cisplatin, reducing the S phase population in the cell cycle, enhancing bladder cancer cell chemosensitivity to cisplatin, and inducing apoptosis [42].